Isolation of rare circulating tumour cells in cancer patients by microchip technology

By S. Nagrath, L. Sequist, S. Maheswaran, D. Bell, D. Irimia, L. Ulkus, Matthew R. Smith, E. Kwak, S. Digumarthy, A. Muzikansky and 5 more. Nature, 2007

3,550 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Oncology

View Paper: https://www.semanticscholar.org/paper/ea1a23c104280a5017a2373a20c7016fea6458d8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. Ming Dao
2. Subra Suresh
3. Mehmet Toner
4. Xiaohui S. Xie
5. Chwee Teck Lim
6. Jongyoon Han
7. Bahram Jalali
8. Tony Jun Huang

In Oncology

1. K. Pantel
2. C. Alix‐Panabières
3. C. Sawyers
4. G. Doyle
5. L. Terstappen
6. M. Miller
7. R. Hynes
8. Shahinoor Begum

Citations in the corpus

• Liquid Biopsy: From Discovery to Clinical Application. (2021, background): “Despite encouraging results initially published more than 10 years ago (62), the high incidences of CTCs in the peripheral blood of patients with solid tumors such as breast, lung, or prostate cancer have never been reproduced.”
• Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer (2009, methodology): “The most likely explanation for the large variation in the reported frequency of CTC by different methods using a similar phenotypic definition is the differences in the actual definition of a CTC [23–30].”
• Nuclear signalling by tumour-associated antigen EpCAM (2009, background): “Consequently, EpCAM-specific antibodies served in many studies to isolate not only cancer stem cells but also very rare circulating tumour cells from metastatic lung, prostate, pancreatic, breast and colon cancer”
• Isolation of circulating tumor cells using a microvortex-generating herringbone-chip (2010, background): “The CTC-Chip provided improved yield and purity of captured CTCs (17), enabling noninvasive serial genotyping of lung cancers carrying epidermal growth factor receptor (EGFR) mutations during the course of therapy with targeted kinase inhibitors (18) and monitoring of patients with either localized ”
• Acoustic separation of circulating tumor cells (2015, background): “In this approach, in combination with magnetic or fluorescence markers, CTCs can be isolated from other blood cells (5, 6).”
• Systems Biology of Cancer Metastasis (2019, background): “While relatively numerous circulating tumor cells (CTCs) are detected in the blood of cancer patients, with reports indicating > 1000 CTCs/ml of blood plasma, disproportionally few metastases are clinically detectable(Nagrath et al., 2007).”